All In Biotech

Drug Trial Radar · NCT07685041

An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jun 27, 2026

Primary completion

Nov 19, 2026

Study completion Jul 20, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with EGFR-TKIs.

Conditions

  • NSCLC

Interventions

  • HS-10504; midazolamDrug

    HS-10504:Participants receive HS-10504 tablets 400 mg (100 mg/tablet, 4 tablets) once daily Midazolam:Participants receive a single oral dose of midazolam oral solution 1 mg (2 mg/mL, 0.5 mL) on C0D1 and C2D20, respectively。

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of PK parameters of Midazolam: CmaxTime frame: 24 hours after administration of Midazolam
  2. Evaluation of PK parameters of Midazolam: AUC0-tTime frame: 24 hours after administration of Midazolam
  3. Evaluation of PK parameters of Midazolam: AUC0-∞Time frame: 24 hours after administration of Midazolam

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.